Onconetix, Inc. business relationships
Companies named in Onconetix, Inc.’s 10-K filed 2026-03-13, and public companies whose annual reports name Onconetix, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 16% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 0 / 100
Named in Onconetix, Inc.’s annual report 8
“we anticipate will be marketed in the U.S. as a lab developed test through our license agreement with LabCorp.” SEC filing
“an exclusive partnership with LabCorp in 2023 pursuant to which LabCorp has the exclusive right to develop and commercialize Proclarix,” SEC filing
“provided by a few mid-sized to large diagnostic companies (e.g., Roche Diagnostics, Abbott Laboratories, Siemens Healthineers AG, DiaSorin” SEC filing
“provided by a few mid-sized to large diagnostic companies (e.g., Roche Diagnostics, Abbott Laboratories, Siemens Healthineers AG, DiaSorin” SEC filing
“provided by a few mid-sized to large diagnostic companies (e.g., Roche Diagnostics, Abbott Laboratories, Siemens Healthineers AG, DiaSorin” SEC filing
“provided by a few mid-sized to large diagnostic companies (e.g., Roche Diagnostics, Abbott Laboratories, Siemens Healthineers AG, DiaSorin” SEC filing
“2025, the Company entered into a license agreement with Immunovia AB, under which it granted exclusive rights to certain intellectual” SEC filing
“development partnership with New Horizon Health Limited, Grand Cayman, Cayman Islands.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.